The competitive advantage of Celector® lies in its ability to sort and select stem cells without any cell manipulation. This is key factor to (1) pass regulatory restrictions, and (2) select/sort stem cells for which there are not, as yet, efficient technologies on the market. Indeed, the main competitor technologies such as the flow-assisted cell sorting (FACS) and the magnetic-assisted cell sorting (MACS®, Miltenyi Corp.) manipulate stem cell using immunomarkers. Immunomarkers moreover are often not available to efficiently select/sort multipotent stem cells such as MSCs. Compared to the competitor technologies on the market, Celector® also presents the following key advantages: lower instrumental investment, lower operation and maintenance costs, disposable cell fractionation device, total preservation of cell viability, reduced operation times

Selected stem cells are extracted from adult tissues. Humans own stem cells into tissues, such as lipoaspirates (product of liposuction), umbilical cord, placenta, dental pulp, epithelium, bone marrow, or blood. Most interesting sources are the so-called \”waste-tissues\”, which are not functional in any way but which contain a certain amount of stem cells. Cells extracted from tissues are introduced into the Celector to separate and isolate stem cells from all cells composing tissue, and sort the “most potent” stem cells through a proprietary methodology that, if compared to analog technologies, does not manipulate the cells at all.

Today cellular biotechnology can rely on a brand new Italian excellence: Stem Sel. We present an innovative and efficient method to select stem cells. We are a university spinoff founded November 2013. Our business then is at its startup phase. Its core activity bases on creating and developing novel, proprietary technologies to decline them into products able to select stem cells from adult tissues with the highest potential, also for future medical use.